Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A.M. Prieur.
Management of children with chronic rheumatism. Similarities and differences with rheumatoid polyarthritis.
Rev Rhum Mal Osteoartic, 57 (1990), pp. 280-286
[2.]
R.E. Petty, T.R. Southwood, P. Manners, et al.
International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis: second revision, Edmonton, 2001.
J Rheumatol, 31 (2004), pp. 390-392
[3.]
W. Thomson, J.H. Barrett, R. Donn, British Paediatric Rheumatology Study Group, et al.
Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients.
Rheumatology (Oxford), 41 (2002), pp. 1183-1189
[4.]
A. Saraux, J.M. Berthelot, V. Devauchelle, et al.
Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis.
J Rheumatol, 30 (2003), pp. 2535-2539
[5.]
S. Dubucquoi, E. Solau-Gervais, D. Lefranc, et al.
Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases.
Ann Rheum Dis, 63 (2004), pp. 415-419
[6.]
D.M. Lee, P.H. Schur.
Clinical utility of the anti-CCP assay in patients with rheumatic diseases.
Ann Rheum Dis, 62 (2003), pp. 870-874
[7.]
X. Zeng, M. Ai, X. Tian, et al.
Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis.
J Rheumatol, 30 (2003), pp. 1451-1455
[8.]
S. Rantapää-Dahlqvist, B.A. De Jong, E. Berglin, et al.
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
Arthritis Rheum, 48 (2003), pp. 2741-2749
[9.]
M. Van Rossum, R. Van Soesbergen, S. De Kort, et al.
Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis.
J Rheumatol, 30 (2003), pp. 825-828
[10.]
J.M. Low, A.K. Chauhan, D.A. Kietz, et al.
Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis.
J Rheumatol, 31 (2004), pp. 1829-1833
[11.]
E.R. Vossenaar, W.J. Van Venrooij.
Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis.
Arthritis Res Ther, 6 (2004), pp. 107-111
[12.]
A.G. Wilson, F.S. De Giovine, A.I.F. Blakemore, et al.
Single base polymorphism in the tumour necrosis factor alpha (TNF-() gene detectable by NcoI restriction of PCR product.
Hum Mol Genet, 1 (1992), pp. 353
[13.]
S. Ozen, M. Alikasifoglu, A. Bakkaloglu, et al.
Tumour necrosis factor alpha G–>A -238 and G–>A -308 polymorphisms in juvenile idiopathic arthritis.
Rheumatology (Oxford), 41 (2002), pp. 223-227
[14.]
F. De Benedetti, M. Massa, P. Pignatti, et al.
Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.
J Clin Invest, 93 (1994), pp. 214-219
[15.]
S. Yokota, T. Miyamae, T. Imagawa, et al.
Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis.
Arthritis Rheum, 52 (2005), pp. 818-825
[16.]
S. Cohen, E. Hurd, J. Cush, et al.
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum, 46 (2002), pp. 614-624
[17.]
V. Pascual, F. Allantaz, E. Arce, et al.
Role of interleukin-1 (IL- 1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.
J Exp Med, 201 (2005), pp. 1479-1486
Copyright © 2005. Sociedad Española de Reumatología